Dolomite and GigaGen Collaborate to Develop Novel Droplet Merging Technology
News Feb 17, 2012
Dolomite has announced its collaboration with GigaGen Inc. (San Francisco, CA) in the development of a novel Droplet Merger Chip for massively parallel single cell genetic analysis.
Measuring just 15mm x 22.5mm, the novel glass microfluidic chip facilitates fast and consistent merging of two individual droplet streams, benefiting a wide range of applications including DNA amplification, biochemical analysis, single cell analysis and high throughput experimentation.
Unlike other methods which incorporate expensive and bulky high voltage electronics to merge droplets using electrostatic forces, the Droplet Merger Chip works by simply “squeezing” droplets together in a carefully designed merging chamber.
The result is a unique microfluidic device, which points the way to low cost disposable chips in future versions.
“A simple and reliable droplet merging technology is an important step forward for us”, said Dr. David Johnson, CEO and founder of GigaGen Inc., adding “We are now using these chips in our game-changing system for massively parallel single cell genetic analysis.”
GigaGen Inc. filed a patent application describing the chip design and its applications in the field of genetic analysis of cells.
As part of a license agreement with GigaGen Inc., Dolomite will be offering the technology later this year to research users in academia and commercial users in a wide range of application areas.
“Many of our customers have asked us for chips to create droplets, merge them, and then carry out further processing and analysis”, commented Dr. Andrew Lovatt, CEO of Dolomite.
Dr. Lovatt continued, “Our partnership with Sphere Fluidics gives us additional capability in selecting the surfactants we use, to optimize droplet behaviour and stability under a wide range of temperature and biological conditions.”
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE
Cracking the Code of Coenzyme Q BiosynthesisNews
Coenzyme Q is a vital cog in the body’s energy-producing machinery, a kind of chemical gateway in the conversion of food into cellular fuel. Researchers are developing new tools to shed light on CoQ function, primarily by finding and defining proteins that have a direct link to the chemical. This includes the development of a new multi-omic strategy to identify the global function of an RNA-binding protein that has long been associated with mitochondria and its role in CoQ biosynthesis.READ MORE
First Successful Gene Therapy Trial Reported for People with Hemophilia ANews
Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.READ MORE